Insider Selling: Kalvista Pharmaceuticals Inc (KALV) Major Shareholder Sells 30,093 Shares of Stock

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) major shareholder Svlsf Iv, Llc sold 30,093 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $29.70, for a total value of $893,762.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Svlsf Iv, Llc also recently made the following trade(s):

  • On Monday, April 8th, Svlsf Iv, Llc sold 22,800 shares of Kalvista Pharmaceuticals stock. The stock was sold at an average price of $29.49, for a total value of $672,372.00.
  • On Monday, March 4th, Svlsf Iv, Llc sold 43,378 shares of Kalvista Pharmaceuticals stock. The stock was sold at an average price of $22.91, for a total value of $993,789.98.
  • On Wednesday, January 2nd, Svlsf Iv, Llc sold 200 shares of Kalvista Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total value of $4,000.00.
  • On Monday, December 31st, Svlsf Iv, Llc sold 25,418 shares of Kalvista Pharmaceuticals stock. The stock was sold at an average price of $20.00, for a total value of $508,360.00.
  • On Friday, December 28th, Svlsf Iv, Llc sold 3,734 shares of Kalvista Pharmaceuticals stock. The stock was sold at an average price of $20.03, for a total value of $74,792.02.

NASDAQ:KALV traded up $0.11 during trading hours on Friday, hitting $25.50. The company had a trading volume of 45,794 shares, compared to its average volume of 163,036. The stock has a market cap of $439.80 million, a P/E ratio of -16.67 and a beta of 2.49. Kalvista Pharmaceuticals Inc has a 1 year low of $7.73 and a 1 year high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.22. The company had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.97 million. Kalvista Pharmaceuticals had a negative return on equity of 19.12% and a negative net margin of 70.08%. Analysts predict that Kalvista Pharmaceuticals Inc will post -1.43 EPS for the current year.

KALV has been the subject of several research reports. Needham & Company LLC initiated coverage on Kalvista Pharmaceuticals in a research report on Wednesday, March 20th. They set a “buy” rating and a $35.00 price target for the company. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $26.00 price target for the company in a research report on Saturday, March 2nd. BidaskClub cut Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 17th. Finally, ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.60.

Large investors have recently modified their holdings of the business. Flinton Capital Management LLC purchased a new stake in Kalvista Pharmaceuticals in the 4th quarter valued at $26,000. Ramsey Quantitative Systems purchased a new position in shares of Kalvista Pharmaceuticals during the 4th quarter worth $35,000. Bank of Montreal Can purchased a new position in shares of Kalvista Pharmaceuticals during the 4th quarter worth $90,000. Virtu Financial LLC purchased a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter worth $216,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Kalvista Pharmaceuticals during the 3rd quarter worth $274,000. Institutional investors own 77.37% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/svlsf-iv-llc-sells-30093-shares-of-kalvista-pharmaceuticals-inc-kalv-stock.html.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: How does a reverse stock split work?

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.